Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Mankind Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹2,216.88Fairly Valued by 2.21%vs CMP ₹2,267.00

P/E (53.0) × ROE (13.9%) × BV (₹376.00) × DY (0.04%)

₹910.20Overvalued by 59.85%vs CMP ₹2,267.00
MoS: -149.1% (Negative)Confidence: 63/100 (Moderate)Models: 1 Fair, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹2,295.4822%Fair (+1.3%)
Graham NumberEarnings₹590.9616%Over (-73.9%)
Earnings PowerEarnings₹184.2813%Over (-91.9%)
DCFCash Flow₹350.8813%Over (-84.5%)
Net Asset ValueAssets₹375.637%Over (-83.4%)
EV/EBITDAEnterprise₹537.719%Over (-76.3%)
Earnings YieldEarnings₹412.807%Over (-81.8%)
ROCE CapitalReturns₹1,555.689%Over (-31.4%)
Revenue MultipleRevenue₹230.035%Over (-89.9%)
Consensus (9 models)₹910.20100%Overvalued
Key Drivers: Wide model spread (₹184–₹2,295) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 3.5%

*Investments are subject to market risks

Analyst Summary

Mankind Pharma Ltd operates in the Pharmaceuticals segment, NSE: MANKIND | BSE: 543904, current market price is ₹2,267.00, market cap is 93,605 Cr.. At a glance, stock P/E is 53.0, ROE is 13.9 %, ROCE is 15.0 %, book value is 376, dividend yield is 0.04 %. The latest intrinsic value estimate is ₹910.20, around 59.9% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹9,498 Cr versus the prior period change of 10.1%, while latest net profit is about ₹1,945 Cr with a prior-period change of 3.7%. The 52-week range shown on this page is 2,727/1,910, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisMankind Pharma Ltd. is a Public Limited Listed company incorporated on 03/07/1991 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL…

This summary is generated from the stock page data available for Mankind Pharma Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

65
Mankind Pharma Ltd scores 65/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health81/100 · Strong
ROCE 15.0% GoodROE 13.9% GoodD/E 0.05 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -1.58% (6mo) SellingDII holding up 1.79% MF buyingPromoter holding at 72.7% Stable
Earnings Quality75/100 · Strong
OPM expanding (23% → 27%) ImprovingWorking capital: -48 days (improving) Efficient
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +6% YoY GrowingProfit (4Q): -16% YoY Declining
Industry Rank50/100 · Moderate
P/E 53.0 vs industry 59.5 In-lineROCE 15.0% vs industry 16.4% Average3Y sales CAGR: 8% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 26, 2026, 1:04 am

Market Cap 93,605 Cr.
Current Price 2,267
Intrinsic Value₹910.20
High / Low 2,727/1,910
Stock P/E53.0
Book Value 376
Dividend Yield0.04 %
ROCE15.0 %
ROE13.9 %
Face Value 1.00
PEG Ratio14.95

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Mankind Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Mankind Pharma Ltd 93,605 Cr. 2,267 2,727/1,91053.0 3760.04 %15.0 %13.9 % 1.00
Cipla Ltd 1,04,608 Cr. 1,295 1,673/1,16622.0 4081.00 %22.7 %17.8 % 2.00
Lupin Ltd 1,04,973 Cr. 2,296 2,381/1,83721.1 4300.52 %21.3 %20.6 % 2.00
Aurobindo Pharma Ltd 82,114 Cr. 1,414 1,460/1,01623.2 6030.28 %14.2 %11.1 % 1.00
Dr Reddys Laboratories Ltd 1,09,933 Cr. 1,317 1,380/1,12119.7 4320.61 %22.7 %18.0 % 1.00
Industry Average19,737.15 Cr1,103.0859.48201.130.36%16.35%15.16%6.10

All Competitor Stocks of Mankind Pharma Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1,9361,8722,0922,2602,2092,0072,4132,5442,4142,1272,5412,6092,633
Expenses 1,5631,4911,5941,6621,6361,4821,8371,7811,6681,6501,8681,9161,854
Operating Profit 374381498598573526576763746477673693778
OPM % 19%20%24%26%26%26%24%30%31%22%26%27%30%
Other Income 3242878492109125139702196478-27
Interest 91244473200162147147138
Depreciation 7167697790879190911059799108
Profit before tax 326355514601571543603810525429494525505
Tax % 24%21%20%21%15%14%16%20%22%11%16%13%11%
Net Profit 249281409473487468506645412382413459449
EPS in Rs 6.217.0110.2211.8012.1611.6812.6216.119.999.2710.0011.1210.89

Last Updated: March 3, 2026, 11:52 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 1:15 am

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3,9183,8294,7945,5307,4868,1278,6299,4989,909
Expenses 3,1413,1243,5504,1515,6446,4296,3586,9307,288
Operating Profit 7787051,2441,3791,8421,6982,2722,5672,621
OPM % 20%18%26%25%25%21%26%27%26%
Other Income 2096494148200163369550334
Interest 1840118482817372595
Depreciation 28386278123270335378409
Profit before tax 9416911,2651,4401,8711,5632,2892,3671,952
Tax % 26%26%24%25%26%20%18%18%
Net Profit 6945149581,0841,3891,2481,8761,9451,704
EPS in Rs 17.3312.8323.9227.0734.6831.1646.8447.1541.28
Dividend Payout % 0%0%32%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-25.94%86.38%13.15%28.14%-10.15%50.32%3.68%
Change in YoY Net Profit Growth (%)0.00%112.32%-73.23%14.98%-38.29%60.47%-46.64%

Mankind Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.

Growth

Last Updated: September 5, 2025, 2:40 pm

Balance Sheet

Last Updated: December 4, 2025, 2:30 am

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 404040404040404141
Reserves 2,9573,0253,6114,6946,5007,7449,66314,59915,469
Borrowings 36019031016885247,2547,248
Other Liabilities 6525968771,0451,7101,5831,7901,9342,104
Total Liabilities 4,0093,8514,5315,8808,9399,37111,51623,82824,862
Fixed Assets 5347789459872,9273,1423,5523,4713,393
CWIP 322211148166387495209207248
Investments 1,4021,6981,7842,3972,5263,1024,21516,68317,611
Other Assets 1,7511,1641,6552,3303,1002,6323,5403,4673,610
Total Assets 4,0093,8514,5315,8808,9399,37111,51623,82824,862

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 5405379601,0228211,7991,7362,322
Cash from Investing Activity + -516-306-396-1,127-1,360-1,041-1,665-12,179
Cash from Financing Activity + 8-240-55989579-710-59,845
Net Cash Flow 31-95-16404866-11
Free Cash Flow 309371795830-1,3601,2191,4561,969
CFO/OP 102%111%99%103%70%123%95%109%

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow418.00515.00-2.00-100.00-687.00-4.00-22.00-5.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 2313322423223334
Inventory Days 120126124169183132160153
Days Payable 1151011131221331037579
Cash Conversion Cycle 273843727352118108
Working Capital Days 95444142264055-48
ROCE %22%36%33%30%21%24%15%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 76.50%76.50%76.50%74.88%74.87%74.87%72.71%72.70%72.67%72.67%72.66%
FIIs 4.18%4.18%6.74%9.87%11.58%12.37%13.34%12.92%13.07%12.83%11.34%
DIIs 4.65%4.56%9.78%11.14%9.94%9.91%11.05%11.47%11.50%11.91%13.26%
Public 14.67%14.76%6.97%4.10%3.61%2.86%2.89%2.89%2.75%2.57%2.75%
No. of Shareholders 1,31,9181,34,7311,27,4491,35,1161,53,4501,63,8541,71,2811,80,5971,79,5491,70,3471,77,539

Shareholding Pattern Chart

No. of Shareholders

Mankind Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Large Cap Fund 4,072,930 1.66 915.43N/AN/AN/A
HDFC Large Cap Fund 2,739,492 1.54 615.732,664,4922026-01-26 08:09:302.81%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 2,312,842 7.64 519.831,986,7222026-03-23 03:35:2216.41%
Nippon India Growth Mid Cap Fund 1,480,100 0.76 332.671,279,0342026-02-23 00:46:5515.72%
Nippon India Large Cap Fund 1,472,280 0.64 330.911,278,3702026-01-26 01:36:4315.17%
Axis ELSS Tax Saver Fund 1,393,048 0.94 313.11,330,9112026-02-23 00:46:554.67%
Aditya Birla Sun Life Flexi Cap Fund 1,365,544 1.22 306.921,325,5442026-03-12 01:03:383.02%
SBI Contra Fund 1,328,039 0.61 298.49N/AN/AN/A
Nippon India Pharma Fund 1,131,195 3.06 254.25907,1542026-03-23 03:35:2224.7%
Axis Focused Fund 1,120,896 2.23 251.931,037,5962026-02-23 00:46:558.03%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 49.2847.7532.0035.7831.59
Diluted EPS (Rs.) 49.2047.6832.0035.7831.59
Cash EPS (Rs.) 63.5058.0340.5240.0734.96
Book Value[Excl.RevalReserv]/Share (Rs.) 347.37239.04190.30157.68121.39
Book Value[Incl.RevalReserv]/Share (Rs.) 347.37239.04190.30157.68121.39
Revenue From Operations / Share (Rs.) 295.87257.99218.41194.25155.13
PBDIT / Share (Rs.) 86.1570.2950.6654.5545.41
PBIT / Share (Rs.) 71.1060.3542.5250.3942.44
PBT / Share (Rs.) 60.6959.5241.4148.9341.94
Net Profit / Share (Rs.) 48.4548.0932.3835.9131.99
NP After MI And SOA / Share (Rs.) 48.2547.7532.0035.7831.59
PBDIT Margin (%) 29.1127.2423.1928.0829.27
PBIT Margin (%) 24.0323.3919.4625.9427.35
PBT Margin (%) 20.5123.0618.9525.1827.03
Net Profit Margin (%) 16.3718.6414.8218.4820.61
NP After MI And SOA Margin (%) 16.3018.5014.6518.4220.36
Return on Networth / Equity (%) 13.8920.4317.2423.2826.79
Return on Capital Employeed (%) 13.2724.5621.6930.9433.87
Return On Assets (%) 7.1715.9813.1915.6719.85
Long Term Debt / Equity (X) 0.380.000.000.010.01
Total Debt / Equity (X) 0.590.020.020.140.05
Asset Turnover Ratio (%) 0.610.950.870.981.01
Current Ratio (X) 1.233.102.321.682.89
Quick Ratio (X) 0.862.371.521.012.01
Inventory Turnover Ratio (X) 6.691.210.500.640.57
Interest Coverage Ratio (X) 8.2883.9845.6337.2990.29
Interest Coverage Ratio (Post Tax) (X) 5.6458.4530.1725.5464.60
Enterprise Value (Cr.) 108143.4991239.850.000.000.00
EV / Net Operating Revenue (X) 8.868.830.000.000.00
EV / EBITDA (X) 30.4232.400.000.000.00
MarketCap / Net Operating Revenue (X) 8.198.900.000.000.00
Price / BV (X) 6.989.830.000.000.00
Price / Net Operating Revenue (X) 8.198.900.000.000.00
EarningsYield 0.010.020.000.000.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Mankind Pharma Ltd. is a Public Limited Listed company incorporated on 03/07/1991 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1991PLC044843 and registration number is 044843. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company's Total Operating Revenue is Rs. 9497.80 Cr. and Equity Capital is Rs. 41.26 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals208, Okhla Industrial Estate, Phase-III, New Delhi Delhi 110020Contact not found
Management
NamePosition Held
Mr. Ramesh JunejaChairman & Wholetime Director
Mr. Rajeev JunejaVice Chairman & Mng.Director
Ms. Sheetal AroraWhole Time Director
Mr. Satish Kumar SharmaWhole Time Director
Mr. Vivek KalraIndependent Director
Mr. Tilokchand Punamchand OstwalIndependent Director
Mr. Bharat AnandIndependent Director
Ms. Vijaya SampathIndependent Director

FAQ

What is the intrinsic value of Mankind Pharma Ltd and is it undervalued?

As of 28 April 2026, Mankind Pharma Ltd's intrinsic value is ₹910.20, which is 59.85% lower than the current market price of ₹2,267.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (13.9 %), book value (₹376), dividend yield (0.04 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Mankind Pharma Ltd?

Mankind Pharma Ltd is trading at ₹2,267.00 as of 28 April 2026, with a FY2026-2027 high of ₹2,727 and low of ₹1,910. The stock is currently in the middle of its 52-week range. Market cap stands at ₹93,605 Cr..

How does Mankind Pharma Ltd's P/E ratio compare to its industry?

Mankind Pharma Ltd has a P/E ratio of 53.0, which is below the industry average of 59.48. This is broadly in line with or below the industry average.

Is Mankind Pharma Ltd financially healthy?

Key indicators for Mankind Pharma Ltd: ROCE of 15.0 % is moderate. Dividend yield is 0.04 %.

Is Mankind Pharma Ltd profitable and how is the profit trend?

Mankind Pharma Ltd reported a net profit of ₹1,945 Cr in Mar 2025 on revenue of ₹9,498 Cr. Compared to ₹1,389 Cr in Mar 2022, the net profit shows an improving trend.

Does Mankind Pharma Ltd pay dividends?

Mankind Pharma Ltd has a dividend yield of 0.04 % at the current price of ₹2,267.00. The company pays dividends, though the yield is modest.

Last Updated: April 26, 2026, 1:04 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543904 | NSE: MANKIND
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Mankind Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports